The data describe a template-driven RIG-I agonist strategy to selectively activate retinoic acid-inducible gene I (RIG-I) signaling inside tumor cells by leveraging overexpressed oncogenic microRNAs, ...
BOSTON, Feb. 23, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced ...
TransCode Therapeutics, Inc. (RNAZ) stock price is 9.61 and TransCode Therapeutics, Inc. (RNAZ) 10-day simple moving average is 9.65. TransCode Therapeutics, Inc. (RNAZ) stock price is 9.61 and ...
Sino-Thai Engineering and Construction Plc, the contractor for the collapsed dome building in Samut Prakan, has blamed unusually strong and gusty wind for the incident, which injured four workers on ...
This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
Featured here, the Cash Flow Statement for Transcode Therapeutics Inc, showing the changes in the company's cash and cash equivalents, broken down to operating, investing and financing activities over ...
TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results